2025 Annual Meeting | Industry Therapeutic Update From argenx: From Discovery to Practice: FcRn Blockade and its Role in CIDP and gMG

Date Monday 04/07/25

Time 06:00 PM - 08:00 PM PDT Add To Calendar

Session Format This program will be presented both in-person and online

On Demand This program is not expected to be available in the meeting's On Demand product.

Event Type Industry Therapeutic Update

Topic(s) General Neurology, Autoimmune Neurology, Neuromuscular and Clinical Neurophysiology (EMG)

Learning Objectives Join us to discover the science of how FcRn inhibition impacts CIDP and gMG. Get ready to hear from expert neurologists on the recognition and burden of CIDP and gMG, and discover the latest clinical data on FcRn inhibition.
This program is NOT accredited for continuing education by any organization. Additionally, Industry Therapeutic Updates program content and the views expressed herein are those of the presenting corporate entity and not of the AAN. These programs are not an official part of the 2025 AAN Annual Meeting education or scientific programs, nor are they endorsed by the AAN. The AAN cannot affirm claims pertaining to FDA off-label medication, research use of pre-FDA drugs, or other research information that might be discussed. Industry Therapeutic Updates are industry events.

CME Available No CME available

Event Timeline
06:00 PM - 08:00 PM PDT	Speaker	Industry Therapeutic Update From argenx: From Discovery to Practice: FcRn Blockade and its Role in CIDP and gMG

��ɫ��

��ɫ��